Poster Presentations-Young Investigators Section-27th May, 10:00-14:00

1)      P067 NATURAL HISTORY OF CHRONIC HBV INFECTION: A COHORT STUDY WITH UP TO 11 YEARS FOLLOW-UP IN BIRJAND HEPATITIS CLINIC, IN EAST OF IRAN, By Tahereh Darvishpour kakhki

2)      P085 HEALTH LITERACY DISPARITIES ABOUT HEPATITIS B:A NATIONAL ASSESSMENT IN IRAN, By Kiandokht Bashiri

3)      P093 DETECTION RESIDUAL HOST CELL DNA BY POLYMERASE CHAIN REACTION TECHNIQUE IN RECOMBINANT HEPATITIS B VACCINE, By Mahdi Paryan

4)      P094 HEPATITIS A SEROPOSITIVITY AMONG NEWLY ADMITTED MEDICAL STUDENTS OF ISFAHAN, KERMANSHAH, AND HAMEDAN: A SEROPREVALENCE STUDY, By Parisa Shoaei

5)      P101 CURCUMIN: A PROMISING NATURAL CHEMOTHERAPEUTIC AGENT IN TREATING HEPATOCELLULAR CARCINOMA, By Mahsa Motavaf

6)      P112 BIOINFORMATICS ANALYSIS IN POLYMERASE GENE OF HEPATITIS B VIRUS ISOLATED FROM IRANIAN PATIENTS, By Ali Namvar

7)      P122 EVALUATION OF ADDING VITAMIN D TO STANDARD HCV REGIMEN (PEG-INTERFERON PLUS RIBAVIRIN) ON EARLY VIROLOGIC RESPONSE (EVR), By Ladan Goshayeshi

8)      P135 SNAPSHOT ON DRUG-RESISTANCE RATE IN NUCLEOS (T)IDE ANALOGUE- NAÏVE AND–TREATED PATIENTS WITH CHRONIC HEPATITIS B IN CLINICAL PRACTICE, By Fatemeh Bakhshizadeh

9)      P138 FATTY ACIDS IN CEREBROSPINAL FLUID IS CORRELATED WITH LIVER ENZYMES TESTS, By Sepideh Ghodoosifar

10)  P141 DISASTER IN HIV PATIENTS: SEVEN CASES WITH QUADRUPLE DEADLY CO-INFECTION, SHIRAZ, IRAN, By Shahab Mahmoudvand

11)  P151 PDCD1 GENETIC DIVERSITY AT POSITION +7785 HAS NOT SHOWN CORRELATION WITH HCV INFECTION, By Razieh Dowran

12)  P153 NON-ALCOHOLIC FATTY LIVER DISEASE AND OBESITY IN CHILDREN: REVIEW ARTICLE, By Sina Dindarian

13)  P159 INTERLEUKIN-10 PROMOTER POLYMORPHISM -1082 A/G (RS1800896) IN PATIENTS WITH HEPATITIS B VIRUS INFECTION, By Farzaneh Sadat Mirfakhar

14)  P161 EFFECT OF DONOR AGE ON THE RESULT OF LIVER TRANSPLANTATION: REVIEW ARTICLE, By Mahdi Bagheri

15)  P163 EVALUATION OF HIGH OXYGEN SATURATION IN CIRRHOTIC PATIENTS, By Ali Adib

16)  P164 RISK FACTORS OF HCV TRANSMISSION AMONG PATIENTS IN MOTAHARI HEPATITIS CLINIC OF SHIRAZ ON 2014-2015; A CROSS SECTIONAL STUDY, By Amir Hossein Babaei

17)  P165 RISK FACTORS AND DEMOGRAPHIC FEATURES OF HBV INFECTION IN PATIENTS REFERRED TO MOTAHARI HEPATITIS CLINIC OF SHIRAZ 2014-2015, By Moeinodin Abedinirad

18)  P168 OUTCOME OF ACCIDENTAL EXPOSURE PRONE TO BLOOD BORNE VIRAL INFECTIONS IN AN EDUCATIONAL HOSPITAL, 6 YEARS FOLLOW UP, By Shabnam Tehrani

19)  P169 EVALUATION OF INTERLEUKIN-27 GENE POLYMORPHISM (2905 T/G) IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION, By Samira Mokhtari

20)  P176 SEVEN YEARS TRENDS IN PREVALENCE OF MAJOR TRANSFUSION-TRANSMISSIBLE VIRAL INFECTIONS IN SHIRAZ BLOOD TRANSFUSION ORGANIZATION, By Leila Kasraian

21)  P178 THE PRE-S2 SEQUENCE MUTATIONS ASSOCIATED WITH HBV DISEASE CONSEQUENCE AMONG DIFFERENT PATIENTS GROUPS, By Mohammad Taghiabadi

22)  P180 THE SURVEY OF PRE-S1 SEQUENCE MUTATIONS AMONG DIFFERENT HBV INFECTED GROUPS, POSSIBLE ASSOCIATION WITH DISEASE CONSEQUENCE, By Mohammad Taghiabadi

23)  P184 THE DOMINANT PREVALENCE OF GENOTYPE D AMONG DIFFERENT HBV INFECTED PATIENT GROUPS, A STUDY FROM REFERRAL CENTER IN SOUTH OF IRAN, By Mohammad Taghiabadi

24)  P190 WILLINGNESS TO RECEIVE TREATMENT FOR HEPATITIS C VIRUS AMONG DRUG INJECTORS ON METHADONE PROGRAM: IMPLICATIONS FOR HCV KNOWLEDGE AND EDUCATION, By Zahra Alam-Mehrjerdi

25)  P192 SHARED METHAMPHETAMINE INJECTION AMONG TREATMENT SEEKERS AND POSITIVE HEPATITIS C STATUS: THE FIRST REPORT FROM PERSIAN IRAN, By Zahra Alam-Mehrjerdi

26)  P211 INTERLEUKIN-28B (RS12979860) GENE VARIATION AND TREATMENT OUTCOME AFTER PEGINTERFERON PLUS RIBAVIRIN THERAPY IN PATIENTS WITH GENOTYPE 1 OF HEPATITIS C VIRUS, By Tahmine Tavakoli

27)  P215 THE EFFECTS OF SINGLE NUCLEOTIDE POLYMORPHISM OF IL28B GENE (RS12980275) ON TREATMENT RESPONSE TO PEGYLATED INTERFERON/RIBAVIRIN IN IRANIAN PATIENTS WITH HEPATITIS C, By Mahsa Zamanian

28)  P217 ASSOCIATION OF IL28B GENE (RS8099917) POLYMORPHISM WITH TREATMENT RESPONSE IN CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGYLATED INTERFERON/RIBAVIRIN IN IRAN, By Mahsa Zamanian

29)  P220 SEROPREVALENCE STUDY OF HEPATITIS B VIRUS AMONG HOSPITALIZED INTRAVENOUS DRUG USERS IN TEHRAN, IRAN (2012-2013), By Tahmineh Kandelouei

30)  P221 VERTICAL HEPATITIS IN A FIVE YEAR PERIOD IN ZABOL HOSPITAL, By Aliyeh Sargazi

31)  P229 LONG TERM THERAPEUTIC CONSEQUENCES IN PATIENTS WITH AUTOIMMUNE HEPATITIS, By Mohammadreza Abdollahi

32)  P230 EVALUATION OF SURVEILLANCE SYSTEMS FOR HEPATITIS B IN IRAN, By Seyed Hossein Hosseini

33)  P242 LACK OF ASSOCIATION BETWEEN IL12A SINGLE NUCLEOTIDE POLYMORPHISM (RS6887695G/C) AND CHRONIC HEPATITIS B VIRUS INFECTION, By Sedigheh Heidarian

34)  P250 SEROPREVALENCE OF HEPATITIS A AND HEPATITIS E VIRUS IN HEALTHY BLOOD DONORS FROM TEHRAN, IRAN, By Khashayar Hesamizadeh

35)  P259 CLONING OF HCV CORE+1 GENE IN BACULOVIRUS EXPRESSION SYSTEM, By Fahimeh Safarnezhad Tameshkel

36)  P286 SURVEILLANCE AND EPIDEMIOLOGY OF HEPATITIS B, C, D AND G IN KHUZESTAN PROVINCE, SOUTHWEST IRAN- A REVIEW, By Amir Pouremamali

37)  P295 COMPARATIVE STUDY ON THE CHEMICAL AND MEDICINAL EFFECTS OF INDIGENOUS SILYBUM MARIANUM FROM EGYPT AND MEDICINAL SILYMARIN FROM CHINA ON THE TREATMENT OF LIVER FIBROSIS ON FEMALE ALBINO RA, By Engy M.A. Elfetoh

38)  P303 OCCULT HEPATITIS B INFECTION IN HEPATITIS C PATIENTS WITH HAEMATOLOGICAL DISORDERS, By Reza Ajudani

39)  P304 SEROPREVALENCE OF HEPATITIS A VIRUS AMONG IRANIAN SOLDIERS, By Mohammad Saeid Rezaee-Zavareh

40)  P305 ARE WOMEN WITH POLYCYSTIC OVARIAN SYNDROME AT A HIGH RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE; A META-ANALYSIS, By Mahdi Ramezani-Binabaj